Tvardi is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. STAT3 is a central mediator across critical fibrotic signaling pathways that drive uncontrolled deposition, proliferation, survival and immune suppression. STAT3 is also positioned at the intersection of many signaling pathways integral to the survival and immune evasion of cancer cells. The company is conducting Phase 2 clinical trials in fibrosis-driven diseases with high unmet need: idiopathic pulmonary fibrosis (NCT05671835) and hepatocellular carcinoma (NCT05440708).
Company Details
- Employees
- 18
- Founded
- -
- Address
- 2450 Holcombe Blvd, Suite X, Houston,tx 77021,united States
- Phone
- 832-413-1362
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tvarditherapeutics.com
- Keywords
- STAT3, Small Molecules, Cancer, Inflammation, Fibrosis.
- HQ
- Houston, TX
Tvardi Therapeutics Questions
Tvardi Therapeutics's helpline number is 832-413-1362
Tvardi Therapeutics's website is tvarditherapeutics.com
Tvardi Therapeutics's LinkedIn profile is https://www.linkedin.com/company/tvardi
Tvardi Therapeutics has
18 employees.
View email and phone details for 18
employees at Tvardi Therapeutics.
Tvardi Therapeutics's industry is
Biotechnology Research
Tvardi Therapeutics's top competitors are
Celltex Therapeutics Corporation,
Avance Biosciences, Inc.,
Hope Biosciences,
Ingeneron,
Salarius Pharmaceuticals,
Iterion Therapeutics,
Moleculin Biotech, Inc.,
Kiromic Biopharma, Inc.,
Immatics,
Cellipont Bioservices.
Tvardi Therapeutics's categories are Biotechnology Research
Tvardi Therapeutics's founding year is 2017
